First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib). Under Kura's collaboration and license agreement with Kyowa Kirin, the sale triggers a $135 million milestone payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. This payment represents a near-term cash inflow tied to commercialization activity for the newly approved therapy.
Positive
- $135 million milestone payment expected prior to year-end
- FDA approval for KOMZIFTI on November 13, 2025
- First U.S. commercial sale confirms product market entry
Negative
- None.
News Market Reaction – KURA
On the day this news was published, KURA declined 2.71%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $1.05B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology showed mixed moves, with names like GERN up 9.02% and SANA up 1.63%, while AVBP, DAWN, and TNGX were modestly down. Momentum scanner only flagged GOSS up 4.7% without news, pointing to stock-specific rather than sector-wide drivers for KURA.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Clinical data update | Positive | -2.6% | ASH 2025 combination data for KOMZIFTI showing strong activity and tolerability. |
| Dec 03 | Investor event | Positive | +7.5% | Announcement of virtual event to discuss ASH 2025 triplet combination data. |
| Dec 02 | Commercial milestone | Positive | -2.7% | First U.S. KOMZIFTI sale triggering <b>$135 million</b> payment from Kyowa Kirin. |
| Nov 25 | Guideline inclusion | Positive | +3.4% | KOMZIFTI added as NCCN Category 2A option for NPM1-mutated AML. |
| Nov 13 | FDA approval | Positive | +0.0% | FDA approval of KOMZIFTI for relapsed/refractory NPM1‑mutated AML. |
Recent KOMZIFTI-related milestones (FDA approval, guidelines inclusion, commercial and clinical updates) have produced mixed price reactions, with both gains and pullbacks, indicating that positive news has not always translated into immediate upside.
Over the past month, Kura Oncology has progressed KOMZIFTI from FDA approval on Nov 13, 2025 to NCCN guideline inclusion and commercial launch. An earlier $30 million milestone from Kyowa Kirin funded Phase 3 KOMET‑017 trials, and Q3 2025 results showed $20.8 million in collaboration revenue with strong liquidity of $549.7 million cash and investments. Today’s $135 million commercialization milestone fits this pattern of non-dilutive funding tied to ziftomenib’s rollout and development.
Market Pulse Summary
This announcement marks a key commercialization step, as the first U.S. KOMZIFTI sale triggers a $135 million payment from Kyowa Kirin. Combined with earlier Q3 2025 collaboration revenue of $20.8 million, a prior $30 million milestone, and cash of $549.7 million, Kura has substantial non-dilutive funding tied to ziftomenib. Investors may watch future sales trends, additional collaboration receipts, and further guideline or label developments for KOMZIFTI.
Key Terms
U.S. Food and Drug Administration regulatory
AI-generated analysis. Not financial advice.
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura’s expectations regarding the receipt and timing of a milestone payment under its collaboration and license agreement with Kyowa Kirin and future development matters. Factors that may cause actual results to differ materially include risks related to Kyowa Kirin’s ability to make the expected milestone payment, including on the anticipated timing; risks associated with the commercialization of KOMZIFTI; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
What triggered the $135 million milestone payment to Kura (KURA)?
When does Kura expect to receive the $135 million payment for KOMZIFTI (KURA)?
When was KOMZIFTI (ziftomenib) approved by the FDA for U.S. use?
How does the KOMZIFTI commercial sale affect Kura Oncology shareholders (KURA)?
Does the announcement confirm KOMZIFTI is being sold in the U.S. now for KURA investors?
Who is responsible for the $135 million milestone payment to Kura (KURA)?
